NEW YORK (AP) — Teva Pharmaceutical Industries Ltd.'s fourth-quarter profit sank 34 percent as an acquisition by the world's largest generic drugmaker improved revenue but raised expenses.
The Israeli company said Wednesday its net income dropped to $506 million, or 57 cents per share, in the three months that ended Dec. 31. That compares to $771 million, or 85 cents per share, in the last quarter of 2010.
Excluding a variety of one-time items, like acquisition, amortization and impairment charges, Teva earned $1.59 per share.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
